How many insider trades does FilingIQ track for HRTX?

FilingIQ tracks 433 Form 4 insider transactions for HRTX (HERON THERAPEUTICS, INC. /DE/), covering filings from Apr 30, 2015 onwards. 24 of those were filed in the last 90 days.

Are HRTX insiders net buyers or net sellers?

Across the full Form 4 history for HRTX, 16 transactions (4%) were open-market purchases and 42 (10%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does HRTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is HRTX in?

HERON THERAPEUTICS, INC. /DE/ (HRTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $218.20M.

HRTX insider trading

NasdaqCM Healthcare

HERON THERAPEUTICS, INC. /DE/ — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

433

Last 90 days

Buys / sells

4% / 10%

Market cap

$218.20M

About HERON THERAPEUTICS, INC. /DE/

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.

Company website: www.herontx.com

HRTX insider activity at a glance

FilingIQ has scored 433 insider transactions for HRTX since Apr 30, 2015. The most recent filing in our index is dated May 6, 2026.

Across the full history, 16 open-market purchases and 42 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on HRTX insider trades is 56.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live HRTX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding HRTX

Rubric Capital Management LP

$27.51M · 1.0% of AUM

Politicians who have traded HRTX

Hinson Arenholz, Ashley

U.S. Rep. , IA · 13 trades

Frequently asked

How many insider trades does FilingIQ track for HRTX?: FilingIQ tracks 433 Form 4 insider transactions for HRTX (HERON THERAPEUTICS, INC. /DE/), covering filings from Apr 30, 2015 onwards. 24 of those were filed in the last 90 days.
Are HRTX insiders net buyers or net sellers?: Across the full Form 4 history for HRTX, 16 transactions (4%) were open-market purchases and 42 (10%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does HRTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is HRTX in?: HERON THERAPEUTICS, INC. /DE/ (HRTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $218.20M.

Methodology & sources

Every HRTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.